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1. Introduction  
Glioblastoma multiforme (GBM) is among the most lethal of all human tumors, with the 
average survival of approximately 1 year from diagnosis (Avgeropoulos and Batchelor, 
1999). In glioblastomas, LOH 10q is the most frequent genetic alteration (69%), followed by 
EGFR amplification (34%), TP53 mutations (31%), p16INK4a deletion (31%), and PTEN 
mutations (24%)(Ohgaki and Kleihues, 2005).  
Treatments of patients with GBM include surgery, radiotherapy and parallel adjuvant 
chemotherapy (Stupp et al., 2005). While radiotherapy has been found to significantly 
prolong survival rates for GBM patients, a poor prognosis and radioresistance are typical 
characteristics of this disease (Stupp et al., 2007).  
The antitumoral drug Temozolomide (TMZ) constitutes, in combination with radiotherapy, 
the current standard of care for glioblastoma (Stupp et al., 2005). However, the action of 
TMZ may be counteracted in tumors by the expression of the DNA repair enzyme MGMT, 
which repairs TMZ-induced DNA lesions (Hegi et al., 2005). MGMT activity and resistance 
to TMZ were highly correlated, indicating that MGMT is a major predictor of response to 
TMZ in glioma cells (Hermisson et al., 2006). According to the authors, collectively, MGMT 
expression and TP53 status may become valuable parameters to predict cell responses to 
TMZ treatment in patients with GBM. Modulation of MSH6, PARP1 and NTL1, DNA repair 
genes involved in mismatch repair and base excision repair (BER), were found at 
transcription and protein levels in GBM cells resistant to TMZ (Zhang et al., 2010).  
Other genotoxic agents exert different effects in GBM cells with different TP53 status. UV 
light (UV-C) (Batista et al., 2009) and chloroethylating agents (ACNU and BCNU) (Batista et 
al., 2007), significantly induce apoptosis in TP53-mutated glioma cells, while WT TP53 cells 
are more sensitive to methylating agents, including TMZ (Hermisson et al., 2006; Roos et al., 
2007).  
Efforts have been made to overcome drug and radio-resistance of GBM cells, but the 
heterogeneity of these tumors seems to be critical, and molecular analysis is an important 
tool to elucidate the mechanisms underlying cellular responses to antitumoral agents. 
Recently, application of genome-scale methodologies has opened the opportunity to study 
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transcript profiles for thousands of genes simultaneously, thus providing a picture on how 
different biological processes can be modulated under irradiation, drug treatment or even 
between different cell types, on the basis of the lists of differentially expressed genes (either 
induced or repressed genes) provided by the microarray experiments. This approach allows 
comparisons between different biological situations (Tusher et al., 2001; Sakamoto-Hojo et 
al., 2003; Fachin et al., 2007; Fachin et al., 2009). In a previous work, several stress 
response/DNA repair genes, such as HSPA9B, INPP5A, PIP5K1A, FANCG, and TPP2 were 
found up-regulated in U343MG-a GBM cells analyzed at 6 h following irradiation with 1 Gy, 
reflecting the radio-resistance of these cells; at this condition, the survival rate was 61%, and 
a broad spectrum of other biological processes was found associated to the list of 
differentially expressed genes in irradiated cells (Bassi et al., 2008). 
TP53 gene plays a role in drug and radioresistance mechanisms, but the complex network of 
signaling pathways involving this gene is not well elucidated. TP53 is a multifunctional 
protein that acts in cell cycle blockage and signaling pathways towards DNA repair, 
contributing to the maintenance of genome integrity in response to a variety of genotoxic 
stresses (Bartussek et al., 1999). Alternatively, TP53 protein triggers a cascade of signaling 
pathways culminating in apoptosis, depending on the extent of DNA damage (Prise et al., 
2005). The TP53 protein is also a transcription factor that regulates the expression of a large 
number of target genes (Vogelstein et al., 2000). Many TP53 target genes have been 
described (el-Deiry, 1998; Horn and Vousden, 2007; Laptenko and Prives, 2006; Sbisa et al., 
2007), and some other targets have been computationally predicted by the analysis of their 
binding sites (Hoh et al., 2002; Smeenk et al., 2008; Veprintsev and Fersht, 2008).  
According to the literature data, there are controversial findings about the outcome of 
patients in relation to the TP53 status of tumors; this gene may positive or negatively 
influences the cell radioresistance, as well as it can exert no influence in cellular responses to 
therapies (McIlwrath et al., 1994; Slichenmyer et al., 1993; Smith et al., 1995).  
2. Objective  
In the present work, we aim to compare gene expression profiles displayed by four GBM 
cell lines in the absence of any kind of treatment, using the microarray method, looking for 
molecular signatures that can provide new clues towards the understanding of GBM 
biology and radioresistance mechanisms. The results on the transcriptional profiles 
presented by a number of genes with different biological functions are discussed on the light 
of literature data regarding GBM cell responses to ionizing radiation and antitumor drugs, 
generally provided by survival assays. 
3. Materials and methods  
3.1 GBM cell lines  
Human GBM U343 MG-a cell line was kindly donated by Dr. James T. Rutka (The Arthur 
and Sonia Labatt Brain Tumour Research Center, Canada), while T98G, U251MG, and 
U87MG were supplied by the American Type Culture Collection (ATCC) (Rockville, 
Maryland, USA). T98G and U251MG cell lines harbor three mutations (TP53, CDKN2A, and 
PTEN) while U343MG-a and U87MG cells are wild-type (WT) for TP53, and mutant (MT) 
for CDKN2A and PTEN genes (Ishii et al., 1999). 
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3.2 Cell culture and total RNA extraction 
For gene expression analysis, cells were thawed from the nitrogen and sub-cultured for four 
passages in the presence of HAM F10 + DEM medium plus 15% fetal bovine serum and kept 
at 37°C and 5% CO2. After the fourth sub-culturing, they were incubated for two days, and 
total RNA extraction was performed in replicate at 48 h, by using the Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The quality of 
RNA samples was evaluated by denaturing agarose gel electrophoresis under standard 
conditions. To remove the contaminating DNA, RNA samples used in cDNA microarrays 
were treated with the Deoxyribonuclease I (Amplification Grade kit, Invitrogen), according 
to manufacturer’s instructions.  
3.3 cDNA microarray method 
Four experiments in duplicate using GBM cells were carried out using a glass slide 
microarray containing 4500 clones of cDNA probe (in duplicates) from the human IMAGE 
Consortium cDNA library [http://image.llnl.gov/image/; kindly provided by Dr. 
Catherine Nguyen (INSERM-CNRS, Marseille, France)], and prepared according to the 
protocol described by Hegde et al (2000).  
Microarrays were spotted onto glass slides (Corning) using a Generation III Array Spotter 
Amersham-Molecular Dynamics according to the manufacturer’s instructions. Each cDNA 
sample was spotted twice on the slide (duplicate spots). The cDNA complex probes were 
prepared using the CyScribe Post Labelling Kit (Amersham Biosciences, England) (Fachin et 
al., 2009). Hybridizations were carried out using an automatic system (Automatic Slide 
Processor, Amersham Biosciences, England) and signals were immediately captured after 
the final wash procedure, using a Generation III laser scanner (Amersham Biosciences, 
England). 
In an attempt to characterize the clones present in the array slide, the gene set was 
submitted to the NIH-DAVID bioinformatic tool, in order to obtain biological functions 
associated with the gene sequences present in the arrays, as well as the number of genes 
associated with each biological process. Among all clones, 2334 were identified by official 
gene symbol (HUGO), distributed in classes according to biological processes (Table 1). 
3.3.1 Data acquisition and gene expression analysis 
The image quantification was performed using the Spot software, 
(http://spot.cmis.csiro.au/spot/, CSIRO, Australia). Filtering, normalization and data 
analysis were done using the R statistical environment (Ihaka and Gentleman, 1996), in 
addition to Limma (Smyth et al., 2005), Bioconductor (Ihaka and Gentleman, 1996), Aroma 
(Bengtsson, 2004) and KTH (Wirta, 2004). The background to each feature was subtracted 
from the foreground value. Furthermore, the spots were evaluated by their circularity and 
calculations on the median versus mean deviation, so that those presenting irregular 
circularity, or with large differences between mean and median values, were considered 
unreliable. The raw data (red – R and green – G) was transformed into MA format before 
normalization, where M = log2(R/G) and A = 1/2 × log2(R × G). These procedures were 
followed by the application of the Print-tip Lowess normalization for each slide. Following 
the normalization procedure, microarray data were exported to tab-delimited tables in MEV 
format and analyzed in MEV (v. 3.1) software (Saeed et al., 2003). The microarrays data 
analysis involved the application of the statistical method SAM - Significance Analysis of  
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GOTERM-BIOLOGICAL PROCESS - FAT % PValue 
GO:0007242~intracellular signaling cascade 10.28 3.90E-09 
GO:0006793~phosphorus metabolic process 9.43 8.50E-16 
GO:0006468~protein amino acid phosphorylation 6.73 6.81E-13 
GO:0008104~protein localization 6.68 2.00E-04 
GO:0042981~regulation of apoptosis 6.47 1.20E-05 
GO:0007049~cell cycle 5.96 2.63E-04 
GO:0033554~cellular response to stress 5.78 1.27E-11 
GO:0006259~DNA metabolic process 4.50 4.42E-06 
GO:0006974~Response to DNA damage stimulus 4.07 5.32E-10 
GO:0006281~DNA repair 3.43 8.95E-11 
GO:0007243~protein kinase cascade 3.43 1.53E-05 
GO:0007167~enzyme linked receptor protein 
signaling pathway 
3.08 1.04E-04 
GO:0009314~response to radiation 1.93 5.82E-04 
GO:0000165~MAPKKK cascade 1.89 1.69E-04 
GO:0022604~regulation of cell morphogenesis 1.41 4.85E-04 
GO:0006310~DNA recombination 1.29 9.19E-05 
GO:0031344~regulation of cell projection 
organization 
1.11 2.05E-04 
GO:0006302~double-strand break repair 0.94 3.35E-05 
GO:0006289~nucleotide-excision repair 0.86 5.76E-05 
GO:0050770~regulation of axonogenesis 0.81 3.26E-04 
GO:0051291~protein heterooligomerization 0.77 2.99E-04 
GO:0050772~positive regulation of axonogenesis 0.51 1.85E-04 
GO:0000723~telomere maintenance 0.51 6.05E-04 
GO:0032925~regulation of activin receptor 
signaling pathway 
0.30 7.62E-04 
Table 1. Percentage of genes for each biological process analyzed for a total of 2334 genes 
present in a glass slide microarray. The array gene set (containing 4300 image clones) was 
submitted to NIH-DAVID (Dennis et al. 2003).  
Microarray (Tusher et al., 2001), with the objective to compare MT versus WT TP53 cell lines 
in terms of expression profiles. We used FDR< 0.68% to select only highly significant 
differentially expressed genes. 
Information regarding biological functions were obtained at S.O.U.R.C.E. (http://genome-
www5.stanford.edu/cgi-bin/SMD/source/source), and NCBI (http://www.ncbi. 
nlm.nih.gov/). Gene functional groups were given by DAVID tool (Dunne et al., 2003), 
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choosing Homo sapiens as the current background, Gene Ontology: GOTERM_BP_FAT as 
parameters, and Functional Annotation Chart as the analyzing tool. The main biological 
functions associated to the list of differentially expressed genes were selected.   
Every modulated gene was compared to a list of previously identified genes with TP53 
binding sites using genome-wide tiling Chromatin immunoprecipitation (ChIP)-on-chip 
approach (Smeenk et al., 2008) or (ChIP) with the paired-end ditag (PET) (Wei et al., 2006) in 
order to point out genes that could be modulated by TP53 transactivation.  
4. Results  
4.1 Transcript profiles displayed by GBM cell lines  
4.1.1 Hierarchical cluster analysis 
Gene expression profiles studied by the cDNA microarray method generated interesting 
results about the transcriptional profiles exhibited by each cell line. Analysis of gene cluster 
uses standard statistical algorithms in order to arrange genes according to similarity of 
expression patterns, and the results can be graphically represented (Eisen et al., 1998). The 
analysis of hierarchical clustering was performed to compare MT and WT TP53 cells 
regarding transcript profiles by using a set of genes previously selected by the SAM 
analysis. The results of the hierarchical clustering showed that MT TP53 cells were grouped 
apart from the WT TP53 cells. The mutant cell lines (T98G and U251) were not separated 
within a gene cluster, indicating more similarity in the basal transcription levels between 
cell lines; in contrast, the proficient cell lines (U87 and U343) were clustered apart from each 
other (Fig.1). 
4.1.2 Differentially expressed genes indicated by Significant Analysis of Microarrays 
(SAM) 
The statistical analysis performed by SAM indicated that MT TP53 cell lines showed 29 
down-regulated and 68 up-regulated genes, compared with WT TP53 cells, for FDR ≤ 0.68%. 
For this small list of highly significant differentially expressed genes, the magnitude of fold-
changes ranged from –1.68 to +1.93 by comparing MT versus WT TP53 (Supp. Table 1). 
For the list of differentially expressed genes, biological gene functions were studied by the 
DAVID-NIH bioinformatic tool (Dennis et al., 2003; Huang da et al., 2009). Out of 97 
modulated genes, 73 were suitable for functional grouping procedure, since 10 genes were 
not grouped and 14 I.D. clones were still unknown. The most relevant categories 
(represented by a variable number of genes) were related to neurological system process 
(11%), regulation of apoptosis (10%), cellular response to stress (8%), regulation of cell 
proliferation (8%), cell-cell adhesion (5%), DNA repair (5%), response to ionizing radiation 
(4%), histone modification (4%), cell division (4%), etc. (Fig.2.). For discussion, we selected 
36 genes on the basis of biological functions that can be possibly related to responses to 
genotoxic agents (Table-2), in order to find out clues for understanding the mechanisms 
underlying the sensitivity or resistance to anticancer therapies. Some of candidate genes that 
may participate in chemo- and/or radioresistance are involved in stress responses (RUVBL2, 
ASNS, RNF8, LIG4 and CAV1) and cell adhesion (CDH8, CDH13, CD93 and ITGA5), and 
other important cathegories, such as regulation of cell proliferation (IGF1R, CDH13, CAV1, 
DUSP22, ADAMTS1, LIG4) and apoptosis (IGF1R, CDH13, IFT57, CRH, HSPB1, ASNS and 
LIG4.  
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Fig. 1. Hierarchical clustering obtained for a gene set previously selected by the SAM 
method (FDR≤0.68%) for the results displayed by four GBM cell lines (T98G, U251MG, 
U343MG-a e U87MG), under normal proliferation in culture. The data set was provided by 4 
experiments in duplicate. Experiments are represented by numbers (1-4) and the replicates 
are represented by letters (A and B). The expression level of each gene is represented 
according to the scale at the top (red indicates induction; green means repression; grey color 
represents data loss). 
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Fig. 2. Main Biological functions associated to the list of differentially expressed genes (out 
of 97 genes, 73 genes were recognized by the system) when comparing MT and WT TP53 
GBM cell lines. The results were analyzed by DAVID-NIH (Dennis et al., 2003; Huang da et 
al., 2009) as a bioinformatic tool to group differentially expressed genes according to their 
functions. 
02468
1
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A comparative analysis of differentially expressed genes (obtained by SAM) was carried out 
with previously identified genes with TP53 binding sites using ChIP-PET and ChIP-on-chip 
analysis (Smeenk et al., 2008; Wei et al., 2006). When comparing with ChIP- PET gene lists, 
we observed only one common gene (LASS6), while the comparison involving the gene list 
of our work with the ChIP-on-chip list, we found five common genes (ARSJ, RCC2, CDH8, 
CDH13 and HTRA1). 
5. Discussion  
Expression profiles displayed by GBM cells provided results to compare these cells  with 
other tumor types (Castells et al., 2010; Castells et al., 2009; Dreyfuss et al., 2009; Marucci et 
al., 2008; Reddy et al., 2008),  normal tissues  (Sallinen et al., 2000), or even regions in the 
same tumor (Mehrian Shai et al., 2005). However, there is no data in the literature 
comparing transcript profiles of GBM cell lines presenting similar genetic background. 
While T98G and U251MG harbor mutations for TP53, CDKN2A, and PTEN, U343MG-a and 
U87MG cell lines differ from others by the presence of a known WT TP53 (Ishii et al., 1999). 
Expression profiles displayed by GBM cell lines were studied in the absence of any 
treatment. The hierarchical clustering analysis compared WT and MT TP53 GBM cells 
regarding transcript profiles using a set of highly significant differentially expressed genes 
previously selected by SAM (FDR ≤ 0.68%). The results showed distinct expression profiles 
for WT TP53 and MT TP53 cells, whose patterns separate the mutant from WT cells. The 
mutant cell lines (T98G and U251MG) were not completely separated from each other 
within the cluster, indicating similarity of transcript patterns between the two cell lines. In 
contrast, TP53 proficient cell lines (U87MG and U343MG-a) were clustered apart from each 
other. These results indicate the potential of the DNA microarray analysis to discriminate 
molecular profiles displayed by GBM cell lines presenting similar mutational background 
for CDKN2A and PTEN genes, but with different TP53 status. 
The statistical analysis performed by SAM (FDR ≤ 0.68%) indicated that MT TP53 cell lines 
showed 28 down-regulated and 66 up-regulated genes, when compared to WT TP53 cells 
(Table. 2). For the list of differentially expressed genes, biological gene functions were 
studied by the DAVID-NIH bioinformatic tool (Dennis et al., 2003; Huang da et al., 2009), 
and several biological processes were associated to the list of significant differentially 
expressed genes, such as: metabolism, response to ionizing radiation, cell adhesion, cell 
motion, apoptosis, DNA repair and transcription. 
In addition, metabolic process was directly related with several biological functions as 
follow: insulin receptor signalling, water soluble vitamin metabolic process, steroid 
hormone receptor signalling, cellular response to nutrient levels, amine biosynthetic process, 
lipid biosynthetic process, calcium ion transport, lipid transport, glucose metabolic process, 
carboxylic acid biosynthetic process, and cellular amino acid derivative metabolic process.  
Other gene functions related to learning/memory, regulation of neuron apoptosis, synaptic 
transmission, and neurological system processes are intrinsic to the neural nature of GBM 
cells. DNA and RNA metabolism/regulation were also associated to several differentially 
expressed genes (Table. 2).  
Three genes (RNF8, CAV1 and LIG4) playing roles in ionizing radiation responses were 
found up-regulated in MT TP53 cells, and this feature may influence the responsiveness to 
radiotherapy. It is already known that ionizing radiation causes DNA double-strand breaks 
(DSBs) that are highly cytotoxic lesions. Cells have a complex DNA-damage response that  
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Symbol CloneID Biological Process 
Fold 
change 
q-
value 
(%) 
SPRY2 40262 
cell-cell signaling, development, organogenesis, 
regulation of signal transduction 
1.93 0.00 
CAV1 24651 
cellular calcium ion homeostasis, cholesterol efflux, 
response to gamma radiation, regulation of apoptosis, 
1.86 0.00 
CDH13 31093 cell adhesion, homophilic cell adhesion 1.61 0.00 
HTRA1 132044 proteolysis and peptidolysis, regulation of cell growth 1.55 0.00 
ADAMT
S1 
34684 
integrin-mediated signaling pathway, negative 
regulation of cell proliferation, heart trabecula formation, 
kidney development, ovulation from ovarian follicle, 
proteolysis 
1.54 0.00 
ITGA5 135671 
cell-matrix adhesion, integrin-mediated signaling 
pathway 
1.35 0.75 
GPR68 22652 
G-protein coupled receptor protein signaling pathway, 
inflammatory response, signal transduction 
1.34 0.00 
GPR44 25625 
G-protein coupled receptor protein signaling pathway, 
immune response, calcium-mediated signaling, 
chemotaxis 
1.34 0.75 
RUVBL2 22267 
chromatin modification, DNA recombination, DNA 
repair, regulation of growth, regulation of transcription 
1.33 0.00 
MKLN1 33715 cell motility, cell-matrix adhesion, signal transduction 1.31 0.00 
KSR1 220655 
Ras protein signal transduction, intracellular signaling 
cascade, protein amino acid phosphorylation 
1.31 0.75 
GNG13 178213 
G-protein coupled receptor protein signaling pathway, 
signal transduction 
1.30 0.75 
CDH8 38939 cell adhesion, homophilic cell adhesion 1.30 0.00 
DNAJA
1 
24473 protein folding, response to unfolded protein 1.28 0.75 
RHOQ 131061 small GTPase mediated signal transduction 1.26 0.00 
FBXL3 25778 protein ubiquitination 1.26 0.00 
CRH 34671 
immune response, learning and/or memory, pregnancy, 
signal transduction,  synaptic transmission 
1.24 0.00 
IGF1R 21519 
axonogenesis, brain development, exocrine pancreas 
development, male sex determination, regulation of 
apoptosis 
1.24 0.00 
ASNS 27208 amino acid biosynthesis 1.23 0.90 
CD93 35503 cell-cell adhesion, macrophage activation, phagocytosis 1.19 0.00 
COPB2 24627 
intracellular protein transport, vesicle-mediated 
transport 
1.18 0.00 
CACNB
2 
34651 Synaptic transmission, ion transport 1.16 0.71 
LASS6 35147 
lipid biosynthetic process, regulation of transcription, 
DNA-dependent 
1.15 0.75 
LIG4 39274 single strand break repair 1.14 0.75 
RNF8 39161 protein ubiquitination 1.14 0.00 
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Symbol CloneID Biological Process 
Fold 
change 
q-
value 
(%) 
KCNIP4 21478 ion transport -1.13 0.00 
RCC2 136887 cell cycle, cell division, mitosis -1.14 0.90 
RBM4 141446 
DNA recombination, DNA repair, DNA replication, 
estrogen receptor signaling pathway, glucocorticoid 
receptor signaling pathway, mRNA splicing 
-1.19 0.00 
DENND
1A 
21467 synaptic vesicle endocytosis -1.21 0.74 
HSPB1 23827 cell death, response to heat -1.23 0.00 
ARSJ 32854 Unknown -1.24 0.00 
ATP6AP
2 
131821 
angiotensin maturation, positive regulation of 
transforming growth factor-beta1 production, regulation 
of MAPKKK cascade 
-1.29 0.00 
UGDH 139835 UDP-glucose metabolism, electron transport -1.41 0.00 
DUSP22 182999 
apoptosis, cell proliferation, development, inactivation of 
MAPK, protein amino acid dephosphorylation 
-1.55 0.00 
PFKFB2 53158 
glucose catabolic process, positive regulation of insulin 
secretion, pyruvate metabolic process 
-1.68 0.00 
Table 2. List of highly significant differentially expressed genes provided by SAM (FDR 
≤0.68%), comparing MT and WT TP53 GBM cell lines. Positive fold-change value means up-
regulation, while negative fold-change value means down-regulation in MT TP53 cells, 
compared to WT TP53 cells. 
includes the spatial reorganization of DSB repair and signalling proteins into subnuclear 
structures surrounding DSB sites (Bartek and Lukas, 2007; Maser et al., 1997). In this context, 
RNF8 protein is an important component of the DNA damage response; it can be recruited 
to the DNA damage sites, thus triggering the formation of ubiquitin conjugates, promoting 
the recruitment of important proteins to DSB sites, thereby enhancing DNA-damage 
checkpoint events (G2/M) and guaranting cell survival (Kolas et al., 2007). There is also 
evidence that RNF8 participates in histone ubiquitylation and protects the genome integrity 
by licensing the DSB-flanking chromatin to concentrate repair factors near the DNA lesions 
(Mailand et al., 2007). LIG4 is also a key protein playing role in DSB repair by non-
homologous end joining (NHEJ) pathway (Helleday et al., 2007), while CAV1 presents a 
tumor suppressor function in non-neoplastic tissue, being down-regulated upon 
transformation, but re-expressed upon progression in metastatic and multidrug-resistant 
tumors (Burgermeister et al., 2008). CAV1 was also associated with multidrug resistance 
(Belanger et al., 2004; Belanger et al., 2003), and radioresistance (Barzan et al., 2010; Cordes 
et al., 2007; Li et al., 2005). 
In MT TP53 cells, other stress response genes (RUVBL2 and ASNS) were up-regulated, while 
RBM4 was down-regulated. RUVBL2 participates in chromatin-remodelling (Lee et al., 
2010), which could also let the lesion available to DNA repair genes. ASNS is a gene whose 
response elements function as an enhancer to mediate the transcriptional activation of the 
gene, either by the amino acid response (AAR) or the unfolded protein response (UPR 
pathway), triggered by amino acid limitation or endoplasmic reticulum stress (Siu et al., 
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2002), respectively. These pathways initiate a wide array of adaptive mechanisms and 
ultimately, if necessary, programmed cell death (Harding et al., 2003; Zinszner et al., 1998);  
The role of RBM4 in response to stress stimulus is the activation of internal ribosome entry 
site (IRES)-mediated translation, promoting the expression of stress-response genes; 
therefore, the down-regulation of RBM4 in MT TP53 cells might compromise  the 
translational regulation of stress-associated mRNAs (Markus and Morris, 2009).  
 Several genes playing roles in cell adhesion were also differentially expressed in GBM cell 
lines, and this result is in accordance with the association of these genes in acquired chemo- 
and radioresistance (Kraus et al., 2002). In the present work, three cadherins (CDH8, CDH13 
and CD93), and one integrin ITGA5 were found up-regulated in MT TP53 cells, relatively to 
WT counterparts. Cadherins are integral membrane proteins that mediate calcium-
dependent cell-cell adhesion. They may play an important role in the development and 
maintenance of tissues, and possibly are involved in the invasion and metastasis of 
malignant tumors. While CDH8 participates in neural circuitry, CD93 is involved in 
phagocytosis (Bohlson et al., 2005), CDH13 play a role in apoptosis (Chan et al., 2008), and 
ITGA5 in cell spreading (Fang et al., 2010).  
A comparative analysis of differentially expressed genes (provided by SAM) was performed 
with previously identified genes with TP53 binding sites; this comparison was possible by 
using ChIP-PET and ChIP-on-chip analyses (Smeenk et al., 2008; Wei et al., 2006).  For the 
ChIP- PET gene lists, we observed only one common gene (LASS6), which was up-regulated 
in MT TP53 cells. LASS6 is a ceramide sintase, producing ceramides that have 
antiproliferative and pro-apoptotic effects (Ruvolo, 2003). This gene plays a role in apoptosis 
induction in colon cancer cells (Schiffmann et al., 2010), and enhanced tumor development 
and growth in vivo in human head and neck squamous cell carcinomas (HNSCCs) (Senkal et 
al., 2010). 
In addition, the comparison involving our modulated gene list, comparing MT and WT 
TP53 GBM cells, using the ChIP-on-chip list, provided five common genes: ARSJ, RCC2, 
CDH8, CDH13 and HTRA1). While CDH8, CDH13 and HTRA1 were up-regulated, ARSJ 
and RCC2 were down-regulated in MT TP53 cells. CDH8 and CDH13 are cadherins and 
were already discussed as possible targets to chemo- and radioresistance (Kraus et al., 
2002). HTRA1 is a tumor suppressor-like factor when overexpressed in cancer cell lines. 
(Baldi et al., 2002; Chien et al., 2004). This gene was also associated to cisplatin therapy 
responses in various cancer types (Catalano et al., 2011; Chien et al., 2006; Komatsu et al., 
2006). These genes cannot be transactivated by TP53, according to the TP53 status in T98G 
and U251MG cells. However, the majority of the genome-wide TP53 target sites can also 
be bounded by overexpressed p63 and p73 in vivo, suggesting that they may possibly 
play an important role at TP53 binding sites (Smeenk et al., 2008). ARSJ and RCC2 genes 
were not described to be related with stress responses or cancer, and were up-regulated in 
WT TP53 GBM cells, compared to MT, and probably, they can be associated to 
transactivation properties of TP53. 
Thus, in the present work, most genes involved in stress responses (RUVBL2, ASNS, 
RNF8, LIG4 and CAV1), cell adhesion (CDH8, CDH13, CD93 and ITGA5), and genes 
associated to p63 and p73 binding sites (LASS6 and HTRA1) were up-regulated in MT 
TP53 cells. At least some of them may have the potential to be directly involved in radio- 
or chemoresistance. Therefore, the loss of TP53 function may compromise cellular 
responses to anticancer agents. 
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It is already known that mechanisms underlying the cellular radiosensitivity seem to vary 
among different cell lineages, but at what extent the radiosensitivity depends on TP53 
function is a matter of investigation since long time ago. Several authors demonstrated that 
the loss of TP53 function decreases the sensitivity of GBM cells to irradiation (Bartussek et 
al., 1999; McIlwrath et al., 1994; Roy et al., 2006; Yount et al., 1996), and the same was 
observed for other tumor types (Fan et al., 1994; Komarova et al., 1997; Merritt et al., 1994). 
However, in primary gliomas, the TP53 mutation confers an improved prognosis in adult 
glioma patients due to a better response to radiation therapy (Tada et al., 1998). This is 
consistent with the results obtained in in vitro studies, in which glioma cells lacking WT 
TP53 function were more susceptible to radiation-induced apoptosis than their isogenic 
counterparts expressing WT TP53 (Hara et al., 2004).  
It is important to emphasize that all these articles in the literature took into account the TP53 
status, but not other mutations inherent to GBM. In the present work, we studied four GBM 
cell lines with different TP53 status; T98G and U251MG are mutated and U343MG-a and 
U87MG are wild-type for TP53 gene, but they are similar regarding the fact that they harbor 
mutations for CDKN2A and PTEN, according to Ishi et al. (1999). In experiments on cell 
survival performed by the  clonogenic survival assay, the results provided by several 
authors indicated that MT TP53 cells were, in general, more radioresistant than WT TP53 
cells (Bassi et al., 2008; Chautard et al., 2010; de la Pena et al., 2006; Lee et al., 2006; Roy et al., 
2006). 
As described above, several differentially expressed genes provided by the comparison 
between MT versus WT TP53 GBM cells are involved in the mechanism of resistance to 
ionizing radiation and/or multidrug resistance. In general, cytotoxicity of DNA damaging 
agents correlates with the induction of DSB, which can be produced directly or indirectly 
into the DNA molecule. Whereas ionizing radiation induces DSB directly, the drug TMZ 
generates DSB only after two or more cycles of DNA replication, as a secondary effect 
(Caporali et al., 2004). Therefore, TP53 mutation has the potential to change the sensitivity of 
GBM cells to anticancer agents currently used in therapy, and probably, the changes in the 
expression profiles exhibited by several genes acting down-stream in the signalling cascade 
of damage responses may compromise the outcome of drug- and radio- therapies. In order 
to understand these alterations in terms of transcript profiles, we are currently studying at 
what extent TP53 status influences gene expression profiles in irradiated GBM cells 
(manuscript in preparation); we found several differentially expressed genes in irradiated MT 
TP53 cells that are probably implicated in tumor resistance; among them, we can mention 
CLSTN2, ROBO2, and BMPR1B (with role in cell-cell adhesion), BTRC, CYP26B1, and ANLN 
(cell cycle regulators). 
However, the data in the literature regarding the role of TP53 in mediating sensitivity to 
anticancer agents still present controversies. It has been reported that the absence of a 
functional TP53 increases TMZ sensitivity in glioma cell lines, an effect that is independent 
of MGMT status (Blough et al., 2011). Glioma cell lines that did not express a functional 
TP53 were significantly more sensitive to TMZ than cell lines that were functionally intact 
for TP53 expression (Blough et al., 2011). An example of this inconsistency comes from the 
results obtained with T98G cell line (MT TP53), in with the role of MGMT in mediating TMZ 
resistance was confirmed by the co-exposure to the MGMT inhibitor O6-BG, causing a 
reduction in the EC50, as evaluated by the clonogenic survival assay (Hermisson et al., 
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2006). Nevertheless, the roles of TP53 in terms of its influence on drug sensitivity are 
difficult to elucidate, since the dependence on the cell type, and the kind of antitumor agent 
used(Fukushima et al., 2009). In addition, the genetic background is also critical, since GBM 
cells often harbor other mutations for cell cycle regulator genes, and other tumor suppressor 
genes, as already mentioned for the four GBM cell lines studied in the present work, which 
carry two other mutations (CDKN2A and PTEN). 
The control of cell proliferation is very critical in the tumor development, and may also be 
influenced by the TP53 status (Facoetti et al., 2008). Several genes playing roles in the 
regulation of cell proliferation were found differentially expressed in MT TP53 cells, 
relatively to WT: IGFR1, CDH13, DUSP22, ADAMTS1, CAV1, and LIG4. These last two 
genes also play a role in stress responses, as mentioned before.  
Tumor growth also depends on the rate of apoptosis (Amirlak and Couldwell, 2003), and 
apoptosis is directly involved in gliomagenesis and resistance towards classical genotoxic 
approaches in cancer therapy. It has been reported that GBM cells are virtually resistant to 
different apoptotic stimuli (Adamson et al., 2009; Eisele and Weller, 2011), but the 
mechanisms underlying these responses are still unclear, and may depend on several 
treatment conditions and type of genotoxic agent. In the present work, the list of 
differentially expressed genes also indicated several genes implicated in apoptosis. Those 
genes, such as IGF1R, CDH13, IFT57, CRH, HSPB1 and ASNS, were up-regulated in MT 
TP53 GBM cells, relatively to WT cells. IGF1R participates in cell proliferation and protection 
of cell death (Trojan et al., 2007), while CDH13, ITF57, CRH and ASNS participates in 
apoptosis induction (Andreeva and Kutuzov, 2010; Chan et al., 2008; Gdynia et al., 2008; 
Gervais et al., 2002; Minas et al., 2007; Siu et al., 2002). Considering that the ability of cells to 
undergo apoptosis is dependent of a complex signaling cascade involving pro- and anti-
apoptotic genes, among other gene classes, the up-regulation of several apoptosis related 
genes in MT TP53 cells might influence responses of GBM cells submitted to anticancer 
agents.  
In this work, we showed some distinct transcript profiles for MT and WT TP53 GBM cells, 
pointing out several genes that might influence cell sensitivity to chemo- and/or 
radiotherapy.  
6. Conclusions 
The present data comparing transcript profiles displayed by GBM cell lines with different 
TP53 status showed that several biological processes were associated to the list of highly 
significant differentially expressed genes. Gene classes associated with those genes (stress 
response, DNA repair, proliferation, cell division, cell adhesion, apoptosis, etc) provided a 
picture on transcript profiles under normal conditions of cell proliferation in cultured GBM 
cell lines. However, these gene classes reflect wide amplitude of cellular processes that 
might be involved in cellular defense mechanisms under conditions of cell injury provoked 
by irradiation or drug treatment. These results support the hypothesis that MT TP53 cells 
might be more resistant than WT TP53 cells to some genotoxic stresses, such as ionizing 
radiation and TMZ. While this hypothesis still should be tested, altogether, the information 
obtained in this work provides a relevant basic contribution towards the understanding of 
GBM responses to therapies, and for designing novel therapeutic strategies for patients with 
GBM, based on their TP53 status, but also considering other gene mutations.  
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7. Supplementary data 
Symbol Gene Name CloneID 
Fold 
change 
q-
value 
(%) 
SPRY2 Sprouty homolog 2 (Drosophila) 40262 1.93 0.00 
CAV1 Caveolin 1, caveolae protein, 22kDa 24651 1.86 0.00 
MINA MYC induced nuclear antigen 139217 1.79 0.00 
 Clone 25220 mRNA sequence 25220 1.63 0.00 
CDH13 Cadherin 13, H-cadherin (heart) 31093 1.61 0.00 
HTRA1 HtrA serine peptidase 1 132044 1.55 0.00 
ADAMTS1 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 1 
34684 1.54 0.00 
MPND MPN domain containing 24532 1.39 0.00 
ARRB1 Arrestin, beta 1 21814 1.38 0.00 
ACSL4 
Acyl-CoA synthetase long-chain family 
member 4 
133988 1.36 0.00 
ITGA5 
Integrin, alpha 5 (fibronectin receptor, alpha 
polypeptide) 
135671 1.35 0.75 
P4HB Prolyl 4-hydroxylase, beta polypeptide 132702 1.34 0.00 
GPR68 G protein-coupled receptor 68 22652 1.34 0.00 
GPR44 G protein-coupled receptor 44 25625 1.34 0.75 
PDLIM1 PDZ and LIM domain 1 135689 1.33 0.00 
RUVBL2 RuvB-like 2 (E. coli) 22267 1.33 0.00 
 In multiple ClusterIDs 261714 1.32 0.00 
 Unknown 134004 1.32 0.00 
ZXDB Zinc finger, X-linked, duplicated B 38972 1.31 0.90 
MKLN1 
Muskelin 1, intracellular mediator 
containing kelch motifs 
33715 1.31 0.00 
LARP4 
La ribonucleoprotein domain family, 
member 4 
41347 1.31 0.71 
KSR1 Kinase suppressor of ras 1 220655 1.31 0.75 
JAKMIP1 
Janus kinase and microtubule interacting 
protein 1 
32109 1.30 0.00 
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GNG13 
Guanine nucleotide binding protein (G 
protein), gamma 13 
178213 1.30 0.75 
ANKRD42 
MRNA; cDNA DKFZp761C0524 (from clone 
DKFZp761C0524) 
30094 1.30 0.00 
CDH8 cadherin 8, type 2 38939 1.30 0.00 
NRGN 
Neurogranin (protein kinase C substrate, 
RC3) 
178825 1.30 0.75 
USP53 Ubiquitin specific peptidase 53 142468 1.30 0.69 
PIP5K2C 
Phosphatidylinositol-5-phosphate 4-kinase, 
type II, gamma 
133173 1.30 0.75 
WDR34 WD repeat domain 34 133474 1.29 0.00 
TCBA1 Na+/K+ transporting ATPase interacting 2 41427 1.29 0.00 
MGC14376 Chromosome 17 open reading frame 91 24659 1.28 0.00 
DNAJA1 
DnaJ (Hsp40) homolog, subfamily A, 
member 1 
24473 1.28 0.75 
KLF12 Kruppel-like factor 12 34367 1.28 0.00 
UNC13C unc-13 homolog C (C. elegans) 22137 1.27 0.00 
RHOQ Ras homolog gene family, member Q 131061 1.26 0.00 
FBXL3 F-box and leucine-rich repeat protein 3 25778 1.26 0.00 
RP11-
484I6.3 
Chromosome 13 open reading frame 27 24463 1.25 0.00 
 Unknown 132487 1.25 0.75 
CRH Corticotropin releasing hormone 34671 1.24 0.00 
IGF1R insulin-like growth factor 1 receptor 21519 1.24 0.00 
ASNS 
Asparagine synthetase (glutamine-
hydrolyzing) 
27208 1.23 0.90 
CSGlcA-T Chondroitin polymerizing factor 2 39955 1.23 0.75 
NBPF12 Neuroblastoma breakpoint family, member 1 24976 1.23 0.90 
BAMBI 
BMP and activin membrane-bound inhibitor 
homolog (Xenopus laevis) 
41406 1.22 0.00 
PDXK Pyridoxal (pyridoxine, vitamin B6) kinase 25360 1.22 0.00 
 Transcribed locus 136399 1.21 0.75 
TNRC15 Transcribed locus 37482 1.21 0.75 
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 Calneuron 1 39092 1.20 0.75 
3-Mar Membrane-associated ring finger (C3HC4) 3 24707 1.20 0.00 
  Unknown 39306 1.19 0.69 
CD93 CD93 molecule 35503 1.19 0.00 
C20orf39 Transmembrane protein 90B 35704 1.19 0.00 
 In multiple ClusterIDs 41186 1.19 0.71 
 CXXC finger protein 5 136782 1.18 0.00 
PPCDC Phosphopantothenoylcysteine decarboxylase 135984 1.18 0.00 
COPB2 Clone 24627 mRNA sequence 24627 1.18 0.00 
 CDNA FLJ34038 fis, clone FCBBF2005645 38618 1.18 0.00 
FLJ41130 hypothetical LOC401113 40009 1.18 0.00 
CPD Carboxypeptidase D 40521 1.18 0.75 
 Unknown 34967 1.16 0.90 
CACNB2 
calcium channel, voltage-dependent, beta 2 
subunit 
34651 1.16 0.71 
CUTL2 Cut-like homeobox 2 41354 1.16 0.90 
 Unknown 34966 1.15 0.00 
LASS6 LAG1 homolog, ceramide synthase 6 35147 1.15 0.75 
LIG4 Ligase IV, DNA, ATP-dependent 39274 1.14 0.75 
RNF8 Ring finger protein 8 39161 1.14 0.00 
IFT57 
Intraflagellar transport 57 homolog 
(Chlamydomonas) 
34942 1.12 0.00 
PIGO 
Phosphatidylinositol glycan anchor 
biosynthesis, class O 
21678 -1.12 0.71 
KCNIP4 Kv channel interacting protein 4 21478 -1.13 0.00 
RCC2 Regulator of chromosome condensation 2 136887 -1.16 0.90 
PKIB 
Protein kinase (cAMP-dependent, catalytic) 
inhibitor beta 
152289 -1.17 0.00 
DDX18 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
18 
149416 -1.17 0.00 
SIN3A 
SIN3 homolog A, transcription regulator 
(yeast) 
26455 -1.18 0.00 
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RBM4 RNA binding motif protein 4 141446 -1.19 0.00 
NKIRAS2 NFKB inhibitor interacting Ras-like 2 137971 -1.20 0.00 
DENND1A DENN/MADD domain containing 1A 21467 -1.21 0.74 
TMLHE Trimethyllysine hydroxylase, epsilon 21457 -1.22 0.00 
HSPB1 heat shock 27kDa protein 1 23827 -1.23 0.00 
ZNF630 Zinc finger protein 630 141069 -1.24 0.00 
ARSJ Arylsulfatase family, member J 32854 -1.24 0.00 
NUP160 Nucleoporin 160kDa 33299 -1.25 0.00 
SCP2 Sterol carrier protein 2 137004 -1.26 0.68 
NRN1 Neuritin 1 140197 -1.28 0.00 
ATP6AP2 
ATPase, H+ transporting, lysosomal 
accessory protein 2 
131821 -1.29 0.00 
PRPS2 Phosphoribosyl pyrophosphate synthetase 2 146194 -1.32 0.00 
 
Transcribed locus, weakly similar to 
XP_933787.2 PREDICTED: hypothetical 
protein [Homo sapiens] 
53331 -1.34 0.00 
PRSS23 Protease, serine, 23 143887 -1.35 0.00 
CMPK 
Cytidine monophosphate (UMP-CMP) 
kinase 1, cytosolic 
140570 -1.36 0.00 
UGDH UDP-glucose 6-dehydrogenase 139835 -1.41 0.00 
VSNL1 Visinin-like 1 26570 -1.42 0.00 
 Transcribed locus 139645 -1.44 0.00 
SSFA2 Sperm specific antigen 2 140589 -1.45 0.00 
ABCA7 
ATP-binding cassette, sub-family A (ABC1), 
member 7 
182933 -1.45 0.00 
 Unknown 181796 -1.54 0.00 
DUSP22 Dual specificity phosphatase 22 182999 -1.55 0.00 
PFKFB2 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 2 
53158 -1.68 0.00 
 
 
Table 1. List of significantly modulated genes provided by the statistical analysis by SAM 
(FDR ≤0.68%), comparing MT versus WT TP53 GBM cell lines. 
www.intechopen.com
 Molecular Targets of CNS Tumors 
 
282 
8. Acknowledgment 
This study was supported by FAPESP (Fundação de Amparo à pesquisa de São Paulo), proc. 
nº: 04/15611-6,  06/01947-8 and 01953-8/06; CNPq (Conselho Nacional de Desenvolvimento 
Científico e Tecnológico); CAPES (Coordenação de Aperfeiçoamento de Pessoal de nível 
Superior); and FAEPA - HC FMRP/USP (Fundação de Apoio ao Ensino, Pesquisa e 
Assistência). 
9. References 
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., and Bigner, D. D. 
(2009). Glioblastoma multiforme: a review of where we have been and where we 
are going. Expert Opin Investig Drugs 18, 1061-1083. 
Amirlak, B., and Couldwell, W. T. (2003). Apoptosis in glioma cells: review and analysis of 
techniques used for study with focus on the laser scanning cytometer. J Neurooncol 
63, 129-145. 
Andreeva, A. V., and Kutuzov, M. A. (2010). Cadherin 13 in cancer. Genes Chromosomes 
Cancer 49, 775-790. 
Avgeropoulos, N. G., and Batchelor, T. T. (1999). New treatment strategies for malignant 
gliomas. Oncologist 4, 209-224. 
Baldi, A., De Luca, A., Morini, M., Battista, T., Felsani, A., Baldi, F., Catricala, C., Amantea, 
A., Noonan, D. M., Albini, A., et al. (2002). The HtrA1 serine protease is down-
regulated during human melanoma progression and represses growth of metastatic 
melanoma cells. Oncogene 21, 6684-6688. 
Bartek, J., and Lukas, J. (2007). DNA damage checkpoints: from initiation to recovery or 
adaptation. Curr Opin Cell Biol 19, 238-245. 
Bartussek, C., Naumann, U., and Weller, M. (1999). Accumulation of mutant p53(V143A) 
modulates the growth, clonogenicity, and radiochemosensitivity of malignant 
glioma cells independent of endogenous p53 status. Exp Cell Res 253, 432-439. 
Barzan, D., Maier, P., Zeller, W. J., Wenz, F., and Herskind, C. (2010). Overexpression of 
caveolin-1 in lymphoblastoid TK6 cells enhances proliferation after irradiation with 
clinically relevant doses. Strahlenther Onkol 186, 99-106. 
Bassi, C., Mello, S., Cardoso, R., Godoy, P., Fachin, A., Junta, C., Sandrin-Garcia, P., Carlotti, 
C., Falcao, R., Donadi, E., et al. (2008). Transcriptional changes in U343 MG-a 
glioblastoma cell line exposed to ionizing radiation. Hum Exp Toxicol 27, 919-929. 
Batista, L. F., Roos, W. P., Christmann, M., Menck, C. F., and Kaina, B. (2007). Differential 
sensitivity of malignant glioma cells to methylating and chloroethylating anticancer 
drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand 
breaks. Cancer Res 67, 11886-11895. 
Batista, L. F., Roos, W. P., Kaina, B., and Menck, C. F. (2009). p53 mutant human glioma cells 
are sensitive to UV-C-induced apoptosis due to impaired cyclobutane pyrimidine 
dimer removal. Mol Cancer Res 7, 237-246. 
Belanger, M. M., Gaudreau, M., Roussel, E., and Couet, J. (2004). Role of caveolin-1 in 
etoposide resistance development in A549 lung cancer cells. Cancer Biol Ther 3, 
954-959. 
www.intechopen.com
 Portrait of Transcriptional Expression Profiles Displayed by Different Glioblastoma Cell Lines 
 
283 
Belanger, M. M., Roussel, E., and Couet, J. (2003). Up-regulation of caveolin expression by 
cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs 14, 281-287. 
Blough, M. D., Beauchamp, D. C., Westgate, M. R., Kelly, J. J., and Cairncross, J. G. (2011). 
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and 
brain tumor initiating cells from glioblastoma. J Neurooncol 102, 1-7. 
Bohlson, S. S., Zhang, M., Ortiz, C. E., and Tenner, A. J. (2005). CD93 interacts with the PDZ 
domain-containing adaptor protein GIPC: implications in the modulation of 
phagocytosis. J Leukoc Biol 77, 80-89. 
Burgermeister, E., Liscovitch, M., Rocken, C., Schmid, R. M., and Ebert, M. P. (2008). Caveats 
of caveolin-1 in cancer progression. Cancer Lett 268, 187-201. 
Caporali, S., Falcinelli, S., Starace, G., Russo, M. T., Bonmassar, E., Jiricny, J., and D'Atri, S. 
(2004). DNA damage induced by temozolomide signals to both ATM and ATR: role 
of the mismatch repair system. Mol Pharmacol 66, 478-491. 
Castells, X., Acebes, J. J., Boluda, S., Moreno-Torres, A., Pujol, J., Julia-Sape, M., Candiota, A. 
P., Arino, J., Barcelo, A., and Arus, C. (2010). Development of a predictor for human 
brain tumors based on gene expression values obtained from two types of 
microarray technologies. OMICS 14, 157-164. 
Castells, X., Garcia-Gomez, J. M., Navarro, A., Acebes, J. J., Godino, O., Boluda, S., Barcelo, 
A., Robles, M., Arino, J., and Arus, C. (2009). Automated brain tumor biopsy 
prediction using single-labeling cDNA microarrays-based gene expression 
profiling. Diagn Mol Pathol 18, 206-218. 
Catalano, V., Mellone, P., d'Avino, A., Shridhar, V., Staccioli, M. P., Graziano, F., Giordani, 
P., Rossi, D., Baldelli, A. M., Alessandroni, P., et al. (2011). HtrA1, a potential 
predictor of response to cisplatin-based combination chemotherapy in gastric 
cancer. Histopathology. 
Chan, D. W., Lee, J. M., Chan, P. C., and Ng, I. O. (2008). Genetic and epigenetic inactivation 
of T-cadherin in human hepatocellular carcinoma cells. Int J Cancer 123, 1043-1052. 
Chautard, E., Loubeau, G., Tchirkov, A., Chassagne, J., Vermot-Desroches, C., Morel, L., and 
Verrelle, P. (2010). Akt signaling pathway: a target for radiosensitizing human 
malignant glioma. Neuro Oncol 12, 434-443. 
Chien, J., Aletti, G., Baldi, A., Catalano, V., Muretto, P., Keeney, G. L., Kalli, K. R., Staub, J., 
Ehrmann, M., Cliby, W. A., et al. (2006). Serine protease HtrA1 modulates 
chemotherapy-induced cytotoxicity. J Clin Invest 116, 1994-2004. 
Chien, J., Staub, J., Hu, S. I., Erickson-Johnson, M. R., Couch, F. J., Smith, D. I., Crowl, R. M., 
Kaufmann, S. H., and Shridhar, V. (2004). A candidate tumor suppressor HtrA1 is 
downregulated in ovarian cancer. Oncogene 23, 1636-1644. 
Cordes, N., Frick, S., Brunner, T. B., Pilarsky, C., Grutzmann, R., Sipos, B., Kloppel, G., 
McKenna, W. G., and Bernhard, E. J. (2007). Human pancreatic tumor cells are 
sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene 26, 6851-
6862. 
de la Pena, L., Burgan, W. E., Carter, D. J., Hollingshead, M. G., Satyamitra, M., 
Camphausen, K., and Tofilon, P. J. (2006). Inhibition of Akt by the 
alkylphospholipid perifosine does not enhance the radiosensitivity of human 
glioma cells. Mol Cancer Ther 5, 1504-1510. 
www.intechopen.com
 Molecular Targets of CNS Tumors 
 
284 
Dreyfuss, J. M., Johnson, M. D., and Park, P. J. (2009). Meta-analysis of glioblastoma 
multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol 
Cancer 8, 71. 
Eisele, G., and Weller, M. (2011). Targeting apoptosis pathways in glioblastoma. Cancer Lett. 
Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. (1998). Cluster analysis and 
display of genome wide expression patterns. Proc Natl Acad Sci U S A 95, 14863-
14868. 
el-Deiry, W. S. (1998). Regulation of p53 downstream genes. Semin Cancer Biol 8, 345-357. 
Facoetti, A., Ranza, E., and Nano, R. (2008). Proliferation and programmed cell death: role of 
p53 protein in high and low grade astrocytoma. Anticancer Res 28, 15-19. 
Fan, S., el-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, 
I., Kohn, K. W., and O'Connor, P. M. (1994). p53 gene mutations are associated with 
decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer 
Res 54, 5824-5830. 
Fang, Z., Yao, W., Xiong, Y., Zhang, J., Liu, L., Li, J., Zhang, C., and Wan, J. (2010). 
Functional elucidation and methylation-mediated downregulation of ITGA5 gene 
in breast cancer cell line MDA-MB-468. J Cell Biochem 110, 1130-1141. 
Fukushima, T., Takeshima, H., and Kataoka, H. (2009). Anti-glioma therapy with 
temozolomide and status of the DNA-repair gene MGMT. Anticancer Res 29, 4845-
4854. 
Gdynia, G., Lehmann-Koch, J., Sieber, S., Tagscherer, K. E., Fassl, A., Zentgraf, H., 
Matsuzawa, S., Reed, J. C., and Roth, W. (2008). BLOC1S2 interacts with the HIPPI 
protein and sensitizes NCH89 glioblastoma cells to apoptosis. Apoptosis 13, 437-
447. 
Gervais, F. G., Singaraja, R., Xanthoudakis, S., Gutekunst, C. A., Leavitt, B. R., Metzler, M., 
Hackam, A. S., Tam, J., Vaillancourt, J. P., Houtzager, V., et al. (2002). Recruitment 
and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel 
partner Hippi. Nat Cell Biol 4, 95-105. 
Hara, S., Nakashima, S., Kiyono, T., Sawada, M., Yoshimura, S., Iwama, T., Banno, Y., 
Shinoda, J., and Sakai, N. (2004). p53-Independent ceramide formation in human 
glioma cells during gamma-radiation-induced apoptosis. Cell Death Differ 11, 853-
861. 
Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., Calfon, M., Sadri, N., Yun, C., 
Popko, B., Paules, R., et al. (2003). An integrated stress response regulates amino 
acid metabolism and resistance to oxidative stress. Mol Cell 11, 619-633. 
Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., Kros, J. M., 
Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005). MGMT gene silencing and 
benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003. 
Helleday, T., Lo, J., van Gent, D. C., and Engelward, B. P. (2007). DNA double-strand break 
repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6, 
923-935. 
Hermisson, M., Klumpp, A., Wick, W., Wischhusen, J., Nagel, G., Roos, W., Kaina, B., and 
Weller, M. (2006). O6-methylguanine DNA methyltransferase and p53 status 
www.intechopen.com
 Portrait of Transcriptional Expression Profiles Displayed by Different Glioblastoma Cell Lines 
 
285 
predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 
96, 766-776. 
Hoh, J., Jin, S., Parrado, T., Edington, J., Levine, A. J., and Ott, J. (2002). The p53MH 
algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci 
U S A 99, 8467-8472. 
Horn, H. F., and Vousden, K. H. (2007). Coping with stress: multiple ways to activate p53. 
Oncogene 26, 1306-1316. 
Kolas, N. K., Chapman, J. R., Nakada, S., Ylanko, J., Chahwan, R., Sweeney, F. D., Panier, S., 
Mendez, M., Wildenhain, J., Thomson, T. M., et al. (2007). Orchestration of the 
DNA-damage response by the RNF8 ubiquitin ligase. Science 318, 1637-1640. 
Komarova, E. A., Chernov, M. V., Franks, R., Wang, K., Armin, G., Zelnick, C. R., Chin, D. 
M., Bacus, S. S., Stark, G. R., and Gudkov, A. V. (1997). Transgenic mice with p53-
responsive lacZ: p53 activity varies dramatically during normal development and 
determines radiation and drug sensitivity in vivo. Embo J 16, 1391-1400. 
Komatsu, M., Hiyama, K., Tanimoto, K., Yunokawa, M., Otani, K., Ohtaki, M., Hiyama, E., 
Kigawa, J., Ohwada, M., Suzuki, M., et al. (2006). Prediction of individual response 
to platinum/paclitaxel combination using novel marker genes in ovarian cancers. 
Mol Cancer Ther 5, 767-775. 
Kraus, A. C., Ferber, I., Bachmann, S. O., Specht, H., Wimmel, A., Gross, M. W., Schlegel, J., 
Suske, G., and Schuermann, M. (2002). In vitro chemo- and radio-resistance in 
small cell lung cancer correlates with cell adhesion and constitutive activation of 
AKT and MAP kinase pathways. Oncogene 21, 8683-8695. 
Laptenko, O., and Prives, C. (2006). Transcriptional regulation by p53: one protein, many 
possibilities. Cell Death Differ 13, 951-961. 
Lee, J. S., Kim, Y., Kim, I. S., Kim, B., Choi, H. J., Lee, J. M., Shin, H. J., Kim, J. H., Kim, J. Y., 
Seo, S. B., et al. (2010). Negative regulation of hypoxic responses via induced Reptin 
methylation. Mol Cell 39, 71-85. 
Lee, Y. J., Chung, D. Y., Lee, S. J., Ja Jhon, G., and Lee, Y. S. (2006). Enhanced 
radiosensitization of p53 mutant cells by oleamide. Int J Radiat Oncol Biol Phys 64, 
1466-1474. 
Li, J., Hassan, G. S., Williams, T. M., Minetti, C., Pestell, R. G., Tanowitz, H. B., Frank, P. G., 
Sotgia, F., and Lisanti, M. P. (2005). Loss of caveolin-1 causes the hyper-
proliferation of intestinal crypt stem cells, with increased sensitivity to whole body 
gamma-radiation. Cell Cycle 4, 1817-1825. 
Mailand, N., Bekker-Jensen, S., Faustrup, H., Melander, F., Bartek, J., Lukas, C., and Lukas, J. 
(2007). RNF8 ubiquitylates histones at DNA double-strand breaks and promotes 
assembly of repair proteins. Cell 131, 887-900. 
Markus, M. A., and Morris, B. J. (2009). RBM4: a multifunctional RNA-binding protein. Int J 
Biochem Cell Biol 41, 740-743. 
Marucci, G., Morandi, L., Magrini, E., Farnedi, A., Franceschi, E., Miglio, R., Calo, D., 
Pession, A., Foschini, M. P., and Eusebi, V. (2008). Gene expression profiling in 
glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. 
Virchows Arch 453, 599-609. 
www.intechopen.com
 Molecular Targets of CNS Tumors 
 
286 
Maser, R. S., Monsen, K. J., Nelms, B. E., and Petrini, J. H. (1997). hMre11 and hRad50 
nuclear foci are induced during the normal cellular response to DNA double strand 
breaks. Mol Cell Biol 17, 6087-6096. 
McIlwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R. (1994). Cell cycle arrests and 
radiosensitivity of human tumor cell lines: dependence on wild-type p53 for 
radiosensitivity. Cancer Res 54, 3718-3722. 
Mehrian Shai, R., Reichardt, J. K., Ya-Hsuan, H., Kremen, T. J., Liau, L. M., Cloughesy, T. F., 
Mischel, P. S., and Nelson, S. F. (2005). Robustness of gene expression profiling in 
glioma specimen samplings and derived cell lines. Brain Res Mol Brain Res 136, 99-
103. 
Merritt, A. J., Potten, C. S., Kemp, C. J., Hickman, J. A., Balmain, A., Lane, D. P., and Hall, P. 
A. (1994). The role of p53 in spontaneous and radiation-induced apoptosis in the 
gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54, 614-617. 
Minas, V., Rolaki, A., Kalantaridou, S. N., Sidiropoulos, J., Mitrou, S., Petsas, G., Jeschke, U., 
Paraskevaidis, E. A., Fountzilas, G., Chrousos, G. P., et al. (2007). Intratumoral CRH 
modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J 
Cancer 97, 637-645. 
Ohgaki, H., and Kleihues, P. (2005). Population-based studies on incidence, survival rates, 
and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol 
Exp Neurol 64, 479-489. 
Prise, K. M., Schettino, G., Folkard, M., and Held, K. D. (2005). New insights on cell death 
from radiation exposure. Lancet Oncol 6, 520-528. 
Reddy, S. P., Britto, R., Vinnakota, K., Aparna, H., Sreepathi, H. K., Thota, B., Kumari, A., 
Shilpa, B. M., Vrinda, M., Umesh, S., et al. (2008). Novel glioblastoma markers with 
diagnostic and prognostic value identified through transcriptome analysis. Clin 
Cancer Res 14, 2978-2987. 
Roos, W. P., Batista, L. F., Naumann, S. C., Wick, W., Weller, M., Menck, C. F., and Kaina, B. 
(2007). Apoptosis in malignant glioma cells triggered by the temozolomide-induced 
DNA lesion O6-methylguanine. Oncogene 26, 186-197. 
Roy, K., Wang, L., Makrigiorgos, G. M., and Price, B. D. (2006). Methylation of the ATM 
promoter in glioma cells alters ionizing radiation sensitivity. Biochem Biophys Res 
Commun 344, 821-826. 
Ruvolo, P. P. (2003). Intracellular signal transduction pathways activated by ceramide and 
its metabolites. Pharmacol Res 47, 383-392. 
Sallinen, S. L., Sallinen, P. K., Haapasalo, H. K., Helin, H. J., Helen, P. T., Schraml, P., 
Kallioniemi, O. P., and Kononen, J. (2000). Identification of differentially expressed 
genes in human gliomas by DNA microarray and tissue chip techniques. Cancer 
Res 60, 6617-6622. 
Sbisa, E., Catalano, D., Grillo, G., Licciulli, F., Turi, A., Liuni, S., Pesole, G., De Grassi, A., 
Caratozzolo, M. F., D'Erchia, A. M., et al. (2007). p53FamTaG: a database resource of 
human p53, p63 and p73 direct target genes combining in silico prediction and 
microarray data. BMC Bioinformatics 8 Suppl 1, S20. 
Schiffmann, S., Ziebell, S., Sandner, J., Birod, K., Deckmann, K., Hartmann, D., Rode, S., 
Schmidt, H., Angioni, C., Geisslinger, G., and Grosch, S. (2010). Activation of 
www.intechopen.com
 Portrait of Transcriptional Expression Profiles Displayed by Different Glioblastoma Cell Lines 
 
287 
ceramide synthase 6 by celecoxib leads to a selective induction of C16:0-ceramide. 
Biochem Pharmacol 80, 1632-1640. 
Senkal, C. E., Ponnusamy, S., Bielawski, J., Hannun, Y. A., and Ogretmen, B. (2010). 
Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective 
regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J 24, 
296-308. 
Siu, F., Bain, P. J., LeBlanc-Chaffin, R., Chen, H., and Kilberg, M. S. (2002). ATF4 is a 
mediator of the nutrient-sensing response pathway that activates the human 
asparagine synthetase gene. J Biol Chem 277, 24120-24127. 
Slichenmyer, W. J., Nelson, W. G., Slebos, R. J., and Kastan, M. B. (1993). Loss of a p53-
associated G1 checkpoint does not decrease cell survival following DNA damage. 
Cancer Res 53, 4164-4168. 
Smeenk, L., van Heeringen, S. J., Koeppel, M., van Driel, M. A., Bartels, S. J., Akkers, R. C., 
Denissov, S., Stunnenberg, H. G., and Lohrum, M. (2008). Characterization of 
genome-wide p53-binding sites upon stress response. Nucleic Acids Res 36, 3639-
3654. 
Smith, M. L., Chen, I. T., Zhan, Q., O'Connor, P. M., and Fornace, A. J., Jr. (1995). 
Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. 
Oncogene 10, 1053-1059. 
Stupp, R., Hegi, M. E., Gilbert, M. R., and Chakravarti, A. (2007). Chemoradiotherapy in 
malignant glioma: standard of care and future directions. J Clin Oncol 25, 4127-
4136. 
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., 
Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005). Radiotherapy 
plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 
987-996. 
Tada, M., Matsumoto, R., Iggo, R. D., Onimaru, R., Shirato, H., Sawamura, Y., and Shinohe, 
Y. (1998). Selective sensitivity to radiation of cerebral glioblastomas harboring p53 
mutations. Cancer Res 58, 1793-1797. 
Trojan, J., Cloix, J. F., Ardourel, M. Y., Chatel, M., and Anthony, D. D. (2007). Insulin-like 
growth factor type I biology and targeting in malignant gliomas. Neuroscience 145, 
795-811. 
Veprintsev, D. B., and Fersht, A. R. (2008). Algorithm for prediction of tumour suppressor 
p53 affinity for binding sites in DNA. Nucleic Acids Res 36, 1589-1598. 
Vogelstein, B., Lane, D., and Levine, A. J. (2000). Surfing the p53 network. Nature 408, 307-
310. 
Wei, C. L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., 
Weng, Z., et al. (2006). A global map of p53 transcription-factor binding sites in the 
human genome. Cell 124, 207-219. 
Yount, G. L., Haas-Kogan, D. A., Vidair, C. A., Haas, M., Dewey, W. C., and Israel, M. A. 
(1996). Cell cycle synchrony unmasks the influence of p53 function on 
radiosensitivity of human glioblastoma cells. Cancer Res 56, 500-506. 
www.intechopen.com
 Molecular Targets of CNS Tumors 
 
288 
Zhang, J., Stevens, M. F., Laughton, C. A., Madhusudan, S., and Bradshaw, T. D. (2010). 
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms 
and potential translational applications. Oncology 78, 103-114. 
Zinszner, H., Kuroda, M., Wang, X., Batchvarova, N., Lightfoot, R. T., Remotti, H., Stevens, 
J. L., and Ron, D. (1998). CHOP is implicated in programmed cell death in response 
to impaired function of the endoplasmic reticulum. Genes Dev 12, 982-995. 
www.intechopen.com
Molecular Targets of CNS Tumors
Edited by Dr. Miklos Garami
ISBN 978-953-307-736-9
Hard cover, 674 pages
Publisher InTech
Published online 22, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Molecular Targets of CNS Tumors is a selected review of Central Nervous System (CNS) tumors with
particular emphasis on signaling pathway of the most common CNS tumor types. To develop drugs which
specifically attack the cancer cells requires an understanding of the distinct characteristics of those cells.
Additional detailed information is provided on selected signal pathways in CNS tumors.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Paulo R. D. V. Godoy, Stephano S. Mello, Daniele A. Magalha ̃es, Flavia S. Donaires, Ana P. Lima-Montaldi,
Patricia Nicolucci, Eduardo A. Donadi, Geraldo A. S. Passos and Elza T. Sakamoto-Hojo (2011). Portrait of
Transcriptional Expression Profiles Displayed by Different Glioblastoma Cell Lines, Molecular Targets of CNS
Tumors, Dr. Miklos Garami (Ed.), ISBN: 978-953-307-736-9, InTech, Available from:
http://www.intechopen.com/books/molecular-targets-of-cns-tumors/portrait-of-transcriptional-expression-
profiles-displayed-by-different-glioblastoma-cell-lines
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
